In a phase 3 trial, Tenpoint Therapeutics’ eye drop—a combination of carbachol and brimonidine—improved vision for patients ...

Patients with presbyopia experienced improvements in near vision after treatment with Brimochol PF in a second phase 3 ...

Tenpoint Therapeutics, Inc., a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate ...

A novel presbyopia drop improves near vision using pupillary constriction to create a pinhole effect, while allowing good distance vision.

Tenpoint Therapeutics, Inc., a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye, today reported positive topline results from BRIO-II, ...

“In our studies, brimonidine increased the magnitude and duration of action of carbachol and reduced the incidence of hyperemia (eye redness) over carbachol alone. BRIMOCHOL™ PF is the only presbyopia ...

Mid-stage presbyopia trials are also being run by Visus Therapeutics on Brimochol (carbachol and brimonidine tartrate) and LENZ Therapeutics on aceclidine. Novartis meanwhile is taking a different ...

Phentolamine acts as a pupil dilator. It's a similar approach to that taken by Visus Therapeutics with Brimochol – based on carbachol which acts like pilocarpine and brimonidine tartrate ...

The table below is a review of notable updates that occurred in December 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

The global mobile health (mHealth) apps and solutions market is projected to experience significant growth, with a compound annual growth rate (CAGR) of 18.18% ...